Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tuvonralimab”

123 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 123 results

Testing effectiveness (Phase 2)Looking for participantsNCT07070700
What this trial is testing

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)
Fudan University 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07117877
What this trial is testing

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian CancerPlatinum Refractory Epithelial Ovarian CancerOvarian Cancer (OvCa)
Fudan University 33
Testing effectiveness (Phase 2)Looking for participantsNCT07601178
What this trial is testing

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

Who this might be right for
TNBC, Triple Negative Breast Cancer
Jiangsu Cancer Institute & Hospital 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413601
What this trial is testing

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 78
Testing effectiveness (Phase 2)Looking for participantsNCT07289997
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Who this might be right for
AFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4AFPGC+1 more
Hebei Medical University Fourth Hospital 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06884982
What this trial is testing

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Who this might be right for
HCC - Hepatocellular Carcinoma
Northern Jiangsu People's Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07286942
What this trial is testing

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

Who this might be right for
NSCLCNSCLC (Non-small Cell Lung Cancer)
Jiangsu Cancer Institute & Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07646301
What this trial is testing

Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Who this might be right for
Uterine Cervical NeoplasmsLocally Advanced
Sun Yat-sen University 103
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07156682
What this trial is testing

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Who this might be right for
Colon CancerMSS/pMMRQL1706
Qilu Hospital of Shandong University 21
Testing effectiveness (Phase 2)Looking for participantsNCT07290010
What this trial is testing

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital 25
Not applicableNot Yet RecruitingNCT07115550
What this trial is testing

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Huai'an First People's Hospital 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07129161
What this trial is testing

Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University 66
Testing effectiveness (Phase 2)Looking for participantsNCT07014150
What this trial is testing

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Resectable
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828873
What this trial is testing

A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131345
What this trial is testing

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Who this might be right for
Malignant MesotheliomaMesothelioma
National Cancer Center, China 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128251
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma (HCC)ImmunotherapyPD-1+2 more
Anhui Provincial Hospital 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07116577
What this trial is testing

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Who this might be right for
mCRC
Jinan Central Hospital 37
Testing effectiveness (Phase 2)Looking for participantsNCT07530445
What this trial is testing

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Who this might be right for
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07372079
What this trial is testing

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Who this might be right for
Breast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors+1 more
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07127822
What this trial is testing

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMSI-H Cancer
Peking University 106
Next Page